Curaleaf Holdings Inc

OTCPK:CURLF

США / Здравоохранение / Фармацевтика

Обзор

Дивиденды

Финансовая отчетность за 5 лет

Цена акций

0,74 USD


Key Metrics	Latest
Total Revenue	1,343 B
Adjusted EBITDA	253,4 M
EBITDA Margin	18,9%
Net Profit Margin	-14,2%
Total Assets	2,95 B
Total Debt	1,063 B

5Y Historical Financial Statements

Summary Financials


Summary Financials

	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	12 Months	Dec-23	Dec-24

Revenue	626.64	1,195.99	1,275.42	1,346.63	1,342.80	1,342.80	1,346.63	1,342.80
% Growth		0.91	0.07	0.06	(0.00)			(0.00)

Adjusted EBITDA	128.59	179.12	220.97	238.76	253.43	253.43	238.76	253.43
% Margin	0.21	0.15	0.17	0.18	0.19	0.19	0.18	0.19

Adjusted EBIT	72.44	58.57	64.99	42.88	20.20	20.20	42.88	20.20
% Margin	0.12	0.05	0.05	0.03	0.02	0.02	0.03	0.02

Adjusted Net Income	(71.15)	(183.03)	(339.19)	(237.44)	(190.36)	(190.36)	(237.44)	(190.36)
% Margin	(0.11)	(0.15)	(0.27)	(0.18)	(0.14)	(0.14)	(0.18)	(0.14)

Adjusted Basic EPS	(0.13)	(0.26)	(0.48)	(0.33)	(0.26)	(0.26)	(0.33)	(0.26)

Подтверждающие расчеты

Income Statement

Balance Sheet

Statement of Cashflows


Income Statement
						Original
USD	Fiscal Year Ending					Latest	Year-to-date Ending
(in millions)	Dec-20	Dec-21	Dec-22	Dec-23	Dec-24	Dec-24	Dec-23	Dec-24
	FY - 4	FY - 3	FY - 2	FY - 1	FY	LTM	YTD-1	YTD

Revenue	627	1,196	1,275	1,347	1,343	1,343	1,347	1,343
% Growth	NA	90.9%	6.6%	5.6%	-0.3%			-0.3%

Cost of Revenue	(236)	(626)	(649)	(732)	(704)	(704)	(732)	(704)
Gross Profit	391	570	626	614	639	639	614	639
% Revenue	62.3%	47.6%	49.1%	45.6%	47.6%	47.6%	45.6%	47.6%

Research and Development	0	0	0	0	0	0	0	0
Selling and Marketing	0	(18)	(11)	(12)	(19)	(19)	(12)	(19)
General and Admin	(258)	(408)	(437)	(423)	(429)	(429)	(423)	(429)
Other Inc / (Exp)	(39)	(128)	(176)	(204)	(210)	(210)	(204)	(210)
Total Operating Exp	(297)	(554)	(624)	(638)	(657)	(657)	(638)	(657)

Operating Income	93	16	2	(24)	(18)	(18)	(24)	(18)
% Revenue	14.9%	1.3%	0.2%	-1.8%	-1.3%	-1.3%	-1.8%	-1.3%

Interest Expense	(63)	(78)	(89)	(100)	(100)	(100)	(100)	(100)
Pre-tax Income	31	(62)	(86)	(124)	(118)	(118)	(124)	(118)
Earnings of Discontinued Ops.	0	0	(112)	(51)	(6)	(6)	(51)	(6)
Provision for Taxes	(88)	(152)	(179)	(115)	(99)	(99)	(115)	(99)
Net Income to Company	(57)	(215)	(377)	(290)	(222)	(222)	(290)	(222)
% Margin	-9.1%	-17.9%	-29.6%	-21.6%	-16.5%	-16.5%	-21.6%	-16.5%

Minority Interest in Earnings	(0)	9	7	9	7	7	9	7
Net Income to Stockholders	(57)	(206)	(370)	(281)	(215)	(215)	(281)	(215)

Preferred Dividends	0	0	0	0	0	0	0	0
Other Adj.	0	0	112	51	(17)	(17)	51	(17)

Net Income to Common	(57)	(206)	(258)	(230)	(232)	(232)	(230)	(232)
% Margin	-9.1%	-17.2%	-20.3%	-17.1%	-17.3%	-17.3%	-17.1%	-17.3%

As Reported
Basic EPS (Continuing Ops)	(0.10)	(0.29)	(0.36)	(0.32)	(0.31)	(0.31)	(0.32)	(0.31)
Diluted EPS (Continuing Ops)	(0.10)	(0.29)	(0.36)	(0.32)	(0.31)	(0.31)	(0.32)	(0.31)

WA Basic Shares Out.	557.19	698.76	711.16	724.12	740.83	740.83	724.12	740.83
WA Diluted Shares Out.	557.19	698.76	711.16	724.12	740.83	740.83	724.12	740.83

EBITDA, EBIT Reconciliation
EBT, Incl. Unusual Items	31	(62)	(86)	(124)	(118)	(118)	(124)	(118)
Addback: Net Interest Expense	63	78	89	100	100	100	100	100
Addback: Other Non Operating Expenses, Total	(1)	0	12	(5)	(5)	(5)	(5)	(5)
Addback: Depreciation & Amortization	56	121	156	196	233	233	196	233
Addback: Restructuring Charges	0	0	34	9	0	0	9	0
Addback: Merger / Acquisition Expenses	0	0	0	0	0	0	0	0
Addback: Goodwill Impairment	0	3	55	51	0	0	51	0
Addback: Gain (Loss) On Sale Of Invest.	(38)	2	(22)	(2)	(5)	(5)	(2)	(5)
Addback: Gain (Loss) On Sale Of Assets	(3)	5	1	9	(5)	(5)	9	(5)
Addback: Asset Writedown	24	11	(7)	7	53	53	7	53
Addback: In Process R&D Expenses	0	0	0	0	0	0	0	0
Addback: Insurance Settlements	0	0	0	0	0	0	0	0
Addback: Legal Settlements	0	0	0	0	0	0	0	0
Addback: Other Unusual Items	(2)	21	(10)	(2)	(0)	(0)	(2)	(0)
Adjusted EBITDA	129	179	221	239	253	253	239	253
% Margin	20.5%	15.0%	17.3%	17.7%	18.9%	18.9%	17.7%	18.9%

Adjusted EBIT	72	59	65	43	20	20	43	20
% Margin	11.6%	4.9%	5.1%	3.2%	1.5%	1.5%	3.2%	1.5%

Adjusted Net Income Reconciliation
Net Income to Company	(57)	(215)	(377)	(290)	(222)	(222)	(290)	(222)
Addback: Unusual Items	(19)	43	51	71	43	43	71	43
Less: Tax Benefit of Unusual Items (26%)	5	(11)	(13)	(19)	(11)	(11)	(19)	(11)
Adjusted Net Income	(71)	(183)	(339)	(237)	(190)	(190)	(237)	(190)
% Margin	-11.4%	-15.3%	-26.6%	-17.6%	-14.2%	-14.2%	-17.6%	-14.2%

Ошибка загрузки

Curaleaf Holdings Inc

OTCPK:CURLF

США / Здравоохранение / Фармацевтика

Финансовая отчетность за 5 лет